Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Hinge Health, Inc. (HNGE) reported an insider stock sale by one of its directors. On 11/21/2025, the reporting person sold 1,250 shares of Class A common stock in an open-market transaction coded as "S" at a weighted average price of $45.6848 per share, within a range of $45.68 to $45.71.
After this transaction, the director beneficially owns 27,750 shares of Hinge Health Class A common stock directly. No derivative securities transactions were reported in this filing.
HNGE insider Kristina Leslie has filed a Form 144 notice covering the proposed sale of 1,250 shares of HNGE common stock through Morgan Stanley Smith Barney LLC on the NYSE. The shares are valued at an aggregate market value of $57,106.00 based on the filing and are part of a class with 37,919,155 shares outstanding.
The filing shows these shares were acquired as restricted stock from the issuer, with 688 shares acquired on 04/01/2025 and 562 shares on 01/01/2025. Over the prior three months, Leslie reported additional open-market sales of HNGE common stock, including 3,813 shares sold on 11/19/2025 for gross proceeds of $166,257.86 and 2,187 shares sold on 11/18/2025 for $88,476.40.
HNGE filed a notice that an affiliated holder plans to sell common stock under Rule 144. The filing covers 15,000 shares of common stock with an aggregate market value of $680,400.00, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE. The filing notes that there were 37,919,155 shares or other units outstanding at the time of the notice.
The shares to be sold were acquired as performance stock units from the issuer on 04/01/2023, with 15,000 securities acquired on that date and the payment nature listed as "N/A." The seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Hinge Health, Inc. (HNGE) reported an insider stock sale by its Chief Financial Officer. On 11/20/2025, the CFO sold 781 shares of Class A common stock at a price of $44.78 per share in an open-market transaction coded as a sale. This transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025, which is designed to help insiders systematically sell shares over time. Following this sale, the CFO beneficially owns 524,467 shares of Hinge Health common stock in direct ownership.
Hinge Health, Inc. insider Bessemer entities reported major share moves. On November 18, 2025, Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P. converted a total of 4,108,707 shares of Class B Common Stock into 4,108,707 shares of Class A Common Stock under terms described in the company’s charter. On the same date, they sold 725,000 shares of Class A Common Stock at a price of $40.05 per share.
After these transactions, the Bessemer funds reported indirect beneficial ownership of 3,383,707 shares of Class A Common Stock, consisting of 1,745,316 shares held by BVP X and 1,638,391 shares held by BVP X Inst. The reporting entities are described as director-level affiliates and 10% owners of Hinge Health, reflecting significant ongoing ownership even after the sale.
Hinge Health, Inc. (HNGE) reported insider activity involving an individual who is both a director and 10% owner, with holdings tied to Bessemer Venture Partners funds. On November 18, 2025, Bessemer Venture Partners X L.P. converted 2,119,271 shares of Class B Common Stock into 2,119,271 shares of Class A Common Stock, and Bessemer Venture Partners X Institutional L.P. converted 1,989,436 Class B shares into 1,989,436 Class A shares.
On the same date, BVP X sold 373,955 shares of Hinge Health Class A Common Stock and BVP X Institutional sold 351,045 Class A shares. The reporting person, a partner at Bessemer Venture Partners, notes only an indirect, passive economic interest in these Bessemer funds and expressly disclaims beneficial ownership beyond any pecuniary interest.
HNGE filed a Form 144 notice for the proposed public sale of 45,370 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE. The filing lists an aggregate market value of $2,000,817.00 for these shares and states that 37,919,155 shares of the same class are outstanding. The seller acquired 781 shares on 11/15/2025 under an employee stock purchase plan and 44,589 shares on 06/01/2025 from restricted stock units, both from the issuer. By signing, the selling holder represents they are not aware of undisclosed material adverse information about HNGE.
Hinge Health, Inc. (HNGE) reported that one of its directors sold Class A common stock in two transactions. On 11/18/2025, the director sold 2,187 shares at an average price of $40.4556, leaving 32,813 shares beneficially owned. On 11/19/2025, the director sold an additional 3,813 shares at a weighted average price of $43.603, with a remaining holding of 29,000 shares, all held directly.
The company notes that the weighted average price on 11/19/2025 reflects individual sale prices between $43.51 and $43.73, and undertakes to provide detailed breakdowns of the shares sold at each price upon request.
Hinge Health, Inc. (HNGE) reported an insider equity transaction by its President on a Form 4. On 11/18/2025, the officer had 15,977 shares of Class A common stock withheld and cancelled at a price of $40.84 per share to cover federal and state tax obligations arising from the vesting of restricted stock units, in an exempt transaction under Section 16b-3(e). After this tax-withholding event, the officer beneficially owned 804,904 shares of Class A common stock, which include 781 shares acquired on November 14, 2025 through the company’s employee stock purchase plan.
Hinge Health, Inc. (HNGE) reported an insider equity transaction by its Chief Financial Officer on 11/18/2025. The filing shows that 34,903 shares of Class A common stock were disposed of at $40.84 per share in a transaction classified as exempt under Section 16b-3(e). These shares were withheld and cancelled to cover federal and state tax obligations arising from the vesting of restricted stock units, rather than being sold in the open market.
After this tax-withholding event, the CFO beneficially owns 525,248 shares of Class A common stock. This total includes 781 shares acquired on November 14, 2025 through the company’s employee stock purchase plan.